Lonidamine: basic science and rationale for treatment of prostatic proliferative disorders.

@article{Brawer2005LonidamineBS,
  title={Lonidamine: basic science and rationale for treatment of prostatic proliferative disorders.},
  author={Michael K. Brawer},
  journal={Reviews in urology},
  year={2005},
  volume={7 Suppl 7},
  pages={S21-6}
}
Normal and hyperplastic prostatic tissues concentrate citrate within the epithelium; however, a unique biochemical property within prostate epithelial cells renders them dependent on glycolysis, rather than the citric acid cycle, for energy production. Lonidamine, an orally administered small molecule that inhibits glycolysis by the inactivation of hexokinase, may represent a unique and novel approach to the treatment of benign prostatic hyperplasia (BPH). Results of a phase II trial of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

Positron emission tomography and colorectal cancer.

The British journal of surgery • 2001
View 1 Excerpt

Expression of the fructose transporter GLUT5 in human breast cancer.

Proceedings of the National Academy of Sciences of the United States of America • 1996
View 1 Excerpt

Similar Papers

Loading similar papers…